CA2258066C - Isolation and purification of paclitaxel, and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column - Google Patents
Isolation and purification of paclitaxel, and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column Download PDFInfo
- Publication number
- CA2258066C CA2258066C CA 2258066 CA2258066A CA2258066C CA 2258066 C CA2258066 C CA 2258066C CA 2258066 CA2258066 CA 2258066 CA 2258066 A CA2258066 A CA 2258066A CA 2258066 C CA2258066 C CA 2258066C
- Authority
- CA
- Canada
- Prior art keywords
- taxane
- taxanes
- source
- column
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940123237 Taxane Drugs 0.000 title claims abstract description 54
- 239000002952 polymeric resin Substances 0.000 title claims abstract description 11
- 229920003002 synthetic resin Polymers 0.000 title claims abstract description 11
- 229930012538 Paclitaxel Natural products 0.000 title claims description 40
- 229960001592 paclitaxel Drugs 0.000 title claims description 40
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims description 40
- 238000000746 purification Methods 0.000 title abstract description 7
- 238000004587 chromatography analysis Methods 0.000 title description 11
- 238000002955 isolation Methods 0.000 title description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 40
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 33
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 claims description 20
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 claims description 19
- 238000004809 thin layer chromatography Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 239000012044 organic layer Substances 0.000 claims description 17
- 239000012452 mother liquor Substances 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 239000002250 absorbent Substances 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 11
- 239000000741 silica gel Substances 0.000 claims description 11
- 229910002027 silica gel Inorganic materials 0.000 claims description 11
- 229930014667 baccatin III Natural products 0.000 claims description 10
- 239000002002 slurry Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 241000015728 Taxus canadensis Species 0.000 claims description 7
- TUSIZTVSUSBSQI-UHFFFAOYSA-N Dihydrocarveol acetate Chemical compound CC1CCC(C(C)=C)CC1OC(C)=O TUSIZTVSUSBSQI-UHFFFAOYSA-N 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 230000002745 absorbent Effects 0.000 claims description 5
- 229930003935 flavonoid Natural products 0.000 claims description 5
- 150000002215 flavonoids Chemical class 0.000 claims description 5
- 235000017173 flavonoids Nutrition 0.000 claims description 5
- 229930013686 lignan Natural products 0.000 claims description 5
- 150000005692 lignans Chemical class 0.000 claims description 5
- 235000009408 lignans Nutrition 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- -1 taxane compound Chemical class 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 241001116500 Taxus Species 0.000 claims description 2
- 241001116498 Taxus baccata Species 0.000 claims description 2
- 241000202349 Taxus brevifolia Species 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 239000003791 organic solvent mixture Substances 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims 3
- 235000009065 Taxus cuspidata Nutrition 0.000 claims 1
- 241001330459 Taxus wallichiana var. wallichiana Species 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical group O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- 238000000926 separation method Methods 0.000 abstract description 8
- 239000012528 membrane Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000013078 crystal Substances 0.000 description 23
- 229910001868 water Inorganic materials 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229920006026 co-polymeric resin Polymers 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000577157 Tsuga dumosa Species 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003834 baccatin III group Chemical group 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A high yield and high purity method for obtaining taxane analogues from a source containing taxanes. The method employs a polymeric resin membrane for separating the analogues under low pressure without the use of complex and expensive separation/purification steps currently provided in the art.
Description
ISOLATION AND PURIFICATION OF PACLITAXEL AND OTHER RELATED TAXANES
BY INDUSTRIAL PREPARATIVE LOW PRESSURE CHROMATOGRAPHY ON A
POLYMERIC RESIN COLUMN
The present invention relates to a separation technique and more particularly, the present invention relates to techniques to separate paclitaxel and related taxanes.
Paclitaxel is a well known chemotherapeutic drug for treatment of various metastatic cancers. It has been approved by FDA and HPB for the treatment of ovarian and breast cancers.
The compound is a natural product, primarily extracted from the bark of the Pacific yew tree, Taxus brevifolia, and is also found in T. baccata, T. walichiana, T.
yunnanensis and T. canadensis.
The concentration of paclitaxel in various raw materials is typically low, for example, on the order of between 0.0004 and 0.01 1% (w/win the bark of Pacific yew. Such low concentration render the extraction and purification of the compound to pharmaceutical grade from raw materials very challenging, and heretofore impractical on a commercial scale. Various normal phase chromatography and reverse phase chromatography as well as low and high pressure column chromatography techniques have been developed to purify paclitaxel from a crude extract of raw material.
The success of low pressure chromatography greatly depends on the nature of the column.
Various problems are associated with the use of silica gel and alumina trioxide, all of which are classical supports of the stationary phase in partition systems. They form a stable stationary phase with most solvent systems, but it is a strong absorbent and may participate in the separation process to the extent that chromatographic behaviour and recovery of samples are affected.
Chromatographic methods have been developed to detect and isolate paclitaxel from various Taxus species on analytical and preparative basis. These isolation processes are mainly conducted on a small laboratory scale and suffer from low selectivity, recovery and high production cost, thereby presenting a serious and unfulfilled need for an economically practicable method for separating the valuable anti-tumor compound paclitaxel from its close analog cephalomanine as well as other closely related taxanes.
BY INDUSTRIAL PREPARATIVE LOW PRESSURE CHROMATOGRAPHY ON A
POLYMERIC RESIN COLUMN
The present invention relates to a separation technique and more particularly, the present invention relates to techniques to separate paclitaxel and related taxanes.
Paclitaxel is a well known chemotherapeutic drug for treatment of various metastatic cancers. It has been approved by FDA and HPB for the treatment of ovarian and breast cancers.
The compound is a natural product, primarily extracted from the bark of the Pacific yew tree, Taxus brevifolia, and is also found in T. baccata, T. walichiana, T.
yunnanensis and T. canadensis.
The concentration of paclitaxel in various raw materials is typically low, for example, on the order of between 0.0004 and 0.01 1% (w/win the bark of Pacific yew. Such low concentration render the extraction and purification of the compound to pharmaceutical grade from raw materials very challenging, and heretofore impractical on a commercial scale. Various normal phase chromatography and reverse phase chromatography as well as low and high pressure column chromatography techniques have been developed to purify paclitaxel from a crude extract of raw material.
The success of low pressure chromatography greatly depends on the nature of the column.
Various problems are associated with the use of silica gel and alumina trioxide, all of which are classical supports of the stationary phase in partition systems. They form a stable stationary phase with most solvent systems, but it is a strong absorbent and may participate in the separation process to the extent that chromatographic behaviour and recovery of samples are affected.
Chromatographic methods have been developed to detect and isolate paclitaxel from various Taxus species on analytical and preparative basis. These isolation processes are mainly conducted on a small laboratory scale and suffer from low selectivity, recovery and high production cost, thereby presenting a serious and unfulfilled need for an economically practicable method for separating the valuable anti-tumor compound paclitaxel from its close analog cephalomanine as well as other closely related taxanes.
Prior art methods disclose the use of various types of chromatographic techniques to separate paclitaxel and related taxanes, including normal phase and reverse phase chromatography on a silica gel or bonded silica gel column. The prior art methods are end up at low yield, high production cost or involved multiple separation steps which were difficult to scale up to large industrial scale production.
Characteristic of the prior art is United States Patent No. 5, 620, 875, issued April 15, 1997, to Hoffman et al. The document teaches the separation of paclitaxel and other taxanes by multiple step hexane extractions and high performance liquid chromatography (HPLC). The process is involved, labor intensive and only provides moderate yields of the desired compounds.
In United States Patent No. 5, 670, 673, issued September 23, 1997 to Rao, the isolation and purification of Taxol and its analogues is delineated. The process includes the use of reverse phase liquid chromatography on a C 18 adsorbent with elution of the adsorbed analogues.
Although a meritorious procedure, limitations exist with this technique in terms of productivity and purity of compounds obtained.
The present invention provides a simple separation method based on a polymeric resin column which is devoid the limitations of the existing methodology.
It is therefore an object of this invention to provide a simple and more cost effective method for economical isolation and purification of the important taxanes, such as I 3-acetyl-9-dihydrobaccatin III, 10-deacetylbaccatin III, baccatin III, cephalomanine and paclitaxel.
Conventional methods for the isolation of taxanes, including paclitaxel, 13-acetyl-9-dihydrobaccatin III and baccatin III generally comprise the steps of extracting taxanes from raw materials with an alcoholic solvent, defatting the extract, and separating and purifying the individual taxane by chromatography.
One aspect of the present invention is to provide a method of isolating and purifying taxane analogues from a source containing taxanes, comprising:
extracting a source of taxanes in an organic extractant;
coating a weak absorbent medium with the extractant and loading the medium in a column, the column containing an absorbent agent;
Characteristic of the prior art is United States Patent No. 5, 620, 875, issued April 15, 1997, to Hoffman et al. The document teaches the separation of paclitaxel and other taxanes by multiple step hexane extractions and high performance liquid chromatography (HPLC). The process is involved, labor intensive and only provides moderate yields of the desired compounds.
In United States Patent No. 5, 670, 673, issued September 23, 1997 to Rao, the isolation and purification of Taxol and its analogues is delineated. The process includes the use of reverse phase liquid chromatography on a C 18 adsorbent with elution of the adsorbed analogues.
Although a meritorious procedure, limitations exist with this technique in terms of productivity and purity of compounds obtained.
The present invention provides a simple separation method based on a polymeric resin column which is devoid the limitations of the existing methodology.
It is therefore an object of this invention to provide a simple and more cost effective method for economical isolation and purification of the important taxanes, such as I 3-acetyl-9-dihydrobaccatin III, 10-deacetylbaccatin III, baccatin III, cephalomanine and paclitaxel.
Conventional methods for the isolation of taxanes, including paclitaxel, 13-acetyl-9-dihydrobaccatin III and baccatin III generally comprise the steps of extracting taxanes from raw materials with an alcoholic solvent, defatting the extract, and separating and purifying the individual taxane by chromatography.
One aspect of the present invention is to provide a method of isolating and purifying taxane analogues from a source containing taxanes, comprising:
extracting a source of taxanes in an organic extractant;
coating a weak absorbent medium with the extractant and loading the medium in a column, the column containing an absorbent agent;
eluting, in a first step, with an organic solvent mixture at a pressure of between 10 and 20 psi to generate fractions containing taxane compounds;
crystallizing the fractions to provide a solid taxane compound and a mother liquor;
concentrating the mother liquor; and eluting, in a second step, with a polar solvent mixture the mother liquor through a polymeric resin to provide at least a second taxane compound.
A further aspect of the present invention is to provide a method of isolating and purifying taxanes from a source containing taxanes, comprising:
providing a source of taxanes;
extracting the taxanes from the source into an organic extraction medium to provide an organic layer containing taxane compounds;
treating a support material with the organic layer;
providing a low pressure column containing an absorbent agent;
eluting, in a first step, an organic solvent through the column to elute purified taxane fractions;
crystallizing the taxane fractions to provide a first taxane analogue and a mother liquor;
eluting, in a second step, the mother liquor through a polymeric resin in a chromatographic column to purify and elute at least a second taxane analogue and a third taxane analogue; and collecting separated taxane analogues.
A still further aspect of the present invention is to provide a method of isolating and purifying taxanes from a source containing taxanes, comprising:
providing a source of taxanes;
extracting the taxanes from the source into an organic extraction medium to provide an organic layer containing taxane compounds;
treating a support material with the organic layer;
providing a low pressure column containing an absorbent agent;
eluting, in a first step, at a pressure of between 10 and 20 psi, an organic solvent through the column to elute purified taxane fractions and remove flavonoid and lignan impurities;
crystallizing the taxane fractions to provide a first taxane analogue and a mother liquor;
crystallizing the fractions to provide a solid taxane compound and a mother liquor;
concentrating the mother liquor; and eluting, in a second step, with a polar solvent mixture the mother liquor through a polymeric resin to provide at least a second taxane compound.
A further aspect of the present invention is to provide a method of isolating and purifying taxanes from a source containing taxanes, comprising:
providing a source of taxanes;
extracting the taxanes from the source into an organic extraction medium to provide an organic layer containing taxane compounds;
treating a support material with the organic layer;
providing a low pressure column containing an absorbent agent;
eluting, in a first step, an organic solvent through the column to elute purified taxane fractions;
crystallizing the taxane fractions to provide a first taxane analogue and a mother liquor;
eluting, in a second step, the mother liquor through a polymeric resin in a chromatographic column to purify and elute at least a second taxane analogue and a third taxane analogue; and collecting separated taxane analogues.
A still further aspect of the present invention is to provide a method of isolating and purifying taxanes from a source containing taxanes, comprising:
providing a source of taxanes;
extracting the taxanes from the source into an organic extraction medium to provide an organic layer containing taxane compounds;
treating a support material with the organic layer;
providing a low pressure column containing an absorbent agent;
eluting, in a first step, at a pressure of between 10 and 20 psi, an organic solvent through the column to elute purified taxane fractions and remove flavonoid and lignan impurities;
crystallizing the taxane fractions to provide a first taxane analogue and a mother liquor;
eluting, in a second step, at a pressure of 30 psi, the mother liquor through a polystyrene DVB
resin in a chromatographic column to purify and elute at least a second taxane analogue and a third taxane analogue;
eluting, in a third step, the second taxane analogue and the third taxane analogue through a normal phase silica gel column to purify the second taxane analogue and the third taxane analogue; and collecting separated taxane analogues.
The initial source of taxanes was the plant material, Taxus canadensis, which is abundant in Eastern Canada. The twigs and needles or mixture thereof from Taxus canadensis were used. The material may be fresh or dried.
The raw material was ground and extracted with methanol at 60 C for five hours and filtered. The methanol extract was mixed with charcoal and left to stand at room temperature for one hour. This was then filtered. The filtrate was concentrated to about 15% of original volume by evaporation. A 1:1 water:dichloromethane mixture (v/v) was added to the concentrate to obtain a paclitaxel enriched portion (organic layer).
The organic layer was concentrated to a reduced volume and coated on a support material, in this case, the supporting material is CeliteTM 545.
The coated material was loaded on to the top of an industrial preparative column, for example, a 150 mm x 1500 mm column and packed with the absorbent agent A1203. The column was eluted with a mixture of hexane:acetone (start 100:0 end at 45:55) under a pressure of between 10 psi and 20 psi. The fractions containing taxanes were collected and analyzed by thin layer chromatography (TLC) and subsequently combined according TLC results.
The fractions collected were then concentrated under vacuum, the resulting material was dissolved in methanol and kept at room temperature overnight. The crystal formed was filtered out and washed with methanol, then recrystallized from acetone. 13-Acetyl-9-dihydrobaccatin III was obtained as white crystal.
The mother liquor was concentrated to dryness and the residue was dissolved in acetone. The acetone solution was mixed with a polymeric resin (DowexTM resin, polystyrene-DVB). The mixture was evaporated under vacuum to remove acetone.
The resulting powder was subjected to low pressure chromatography. The industrial scale (150 mm x 1500 mm) chromatographic column was packed with DowexTM resin and eluted with acetone:water (45:55, vlv) at a flow rate 150 mI/mm under a operating pressure of 30 psi. Fractions of approximately 2L/each were collected and these were monitored by TLC and HPLC. The fractions which contained baccatin III and 10-deacetylbaccatin III were combined and evaporated under vacuum to remove substantially all of the organic solvent, then diluted with water and extracted with CH2CI2. The extract was then concentrated to dryness and the resulting residue was then dissolved in EtOAc and purified by normal phase silica gel column with hexane:EtOAc as the solvent system (start 5:5 end at 35:65). The baccatin III and 10-deacetylbaccatin- III was finally obtained as white powder with a purity of greater than 98%.
The fractions which contained paclitaxel and cephalomanine were combined and evaporated under vacuum to remove substantially all of the acetone, then partitioned between water and CH2CIZ. The organic layer was separated and evaporated to dryness under vacuum. The residue was dissolved in methanol. To the methanol solution approximately 30% (w/v) of water was added and the mixture was warmed to 60 C for five minutes. then kept in room temperature overnight. The crude crystalline solid from the methanol solution was filtered out and dried under vacuum between 70 C and 75 C. The solid was analyzed by HPLC. It consisted approximately 70% of paclitaxel and 25% of cephalomanine, and some other taxanes.
The crude paclitaxel can be processed according to one of three alternative procedures. In a first possibility, it was dissolved in acetone and purified by reverse phase column chromatography. The column was packed with polymeric resin (DiaionTM resin, HP2MG) and eluted with acetonitrile:water (45,55). Paclitaxel was obtained as white crystal with a purity of greater than 99%. Cephalomanine was obtained as a white powder in a purity of greater than 98%.
Alternatively, as a second processing approach, the purification of paclitaxel and cephalomanine was carried out through a chemical reaction process and then purified by bonded silica gel reverse phase column chromatography. The crude paclitaxel, cephalomanine mixture was dissolved in CHZCIZ or CHC13 (1:10, w/v), and reacted with 10 equivalent of bromine in a round bottom flask that placed in an ice bath (between 0 C and C) for approximately 40 minutes. The resulting mixture of paclitaxel and 2",3"-bromocephalomanine were readily separated by a reverse phase chromatographic column (C18 or phenyl), eluting solvent CH3CN:H20 (45:55). Paclitaxel was obtained as white crystal in a purity of greater than 99%. 2",3"-bromocephalomanine was obtained as a mixture of diastereomers, which were reacted with activated zinc in acetic acid at room temperature, and then purified by flash column chromatography to obtain pure cephalomanine having a purity of greater than 95%.
In a third alternative, the paclitaxel and bromocephalomanine were purified through normal phase silica gel column. The eluting solvent systems may comprise hexane:EtOAc (start 6:4 end at 4:6), or CHzCIz:MeZCO (start 8:2 end at 65:35) or CHCI2:EtOAc (start 75:25, end 6:4). From this method, paclitaxel was obtained as white crystal with a purity exceeding 99%, with cephalomanine present in an amount of less than 0.2%.
Having discussed the invention, more precise reference will now be made to the invention by way of the examples.
Approximately 200 kilograms of dried needles and twigs of Taxus canadensis were extracted with 1,000 liters of methanol at 60 C in an industrial multi-functional extractor for five hours and then filtered. The raw materials were extracted with 700 liters of methanol at a temperature of between 55 C and 60 C for another four hours and filtered.
The filtrate was combined and mixed with 10 kilograms of activated carbon (5% w/w) and kept at room temperature for one hour, then filtered to remove the activated carbon. The filtrate was then concentrated to approximately 100 liters under vacuum, then 300 liters of water:
dichloromethane (1:1) was added. The organic layer was collected and the aqueous solution was extracted two more times with 200 liters of dichloromethane. The dichloromethane solution was combined and evaporated under vacuum to become a slurry form, then diluted with 20 liters of acetone.
The acetone solution was coated on to 20 kilograms of Celite 545. The coated material was air dried and was then loaded on to the top of three low pressure industrial chromatographic columns (dimension: 150 x 15 cm). Each column was packed with kilograms of alumina oxide (AI203) absorbent. It will be appreciated that the exact dimension of the columns is not crucial as long as the columns are sufficiently large to hold the amount of A1203 required for the separation. Use of alumina oxide is effective to absorb flavonoids and lignans which are co-extracted from the source material. These are also difficult to remove and become a problem for the final purity of the product paclitaxel.
The columns were eluted with the solvent system hexane:acetone (start 100:0 end at 45:55) under a pressure between 10 and 15 psi with a flow rate at approximately 150 mI/min.
The fractions containing taxanes were collected and combined according to thin layer chromatography (TLC) results, and were then concentrated under vacuum to remove all solvents. The resulting material was dissolved in methanol and kept at room temperature overnight to yield needle-like crystals. The crystals were filtered and recrystallized from acetone to further yield white needle-like crystals identified as 13-acetyl-9dihydrobaccatin III, having a purity of greater than 96% yield (148 grams) (0.074% based on the raw material).
The mother liquid from the 13-acetyl-9dihydrobaccatin III crystallization was concentrated to dryness under vacuum. The residue was dissolved in three liters of acetone. The acetone solution was mixed with 1.5 kilograms of a polystyrene-divinylbenzene, copolymer resin. The mixture was evaporated to remove the solvent and the resulting powder was loaded on the top of a low pressure industrial chromatographic column packed with polystyrene-divinylbenzene copolymer resin, and eluted with 45%
acetone in water at a flow rate of 150 ml/min. under an operating pressure below than 30 psi. Fractions of 2 L/each were collected and these were monitored by TLC and HPLC.
The fractions which contained paclitaxel and cephalomanine were combined and evaporated under vacuum to remove most of the acetone, then diluted with deionized water and extracted three times with 2.5 liter of dichloromethane. The organic layer was concentrated to dryness under vacuum, the residue was dissolved in one liter of methanol.
To the methanol solution, approximately 30% (w/v) of water was added and the mixture was warmed to 60 C for a few minutes then kept at room temperature overnight.
The crude crystalline solid from the methanol solution was filtered out and dried in a vacuum oven at a temperature of between 70 C and 75 C. The solid consisted of approximately 70% paclitaxel and 25% cephalomanine in a yield of 31 grams.
resin in a chromatographic column to purify and elute at least a second taxane analogue and a third taxane analogue;
eluting, in a third step, the second taxane analogue and the third taxane analogue through a normal phase silica gel column to purify the second taxane analogue and the third taxane analogue; and collecting separated taxane analogues.
The initial source of taxanes was the plant material, Taxus canadensis, which is abundant in Eastern Canada. The twigs and needles or mixture thereof from Taxus canadensis were used. The material may be fresh or dried.
The raw material was ground and extracted with methanol at 60 C for five hours and filtered. The methanol extract was mixed with charcoal and left to stand at room temperature for one hour. This was then filtered. The filtrate was concentrated to about 15% of original volume by evaporation. A 1:1 water:dichloromethane mixture (v/v) was added to the concentrate to obtain a paclitaxel enriched portion (organic layer).
The organic layer was concentrated to a reduced volume and coated on a support material, in this case, the supporting material is CeliteTM 545.
The coated material was loaded on to the top of an industrial preparative column, for example, a 150 mm x 1500 mm column and packed with the absorbent agent A1203. The column was eluted with a mixture of hexane:acetone (start 100:0 end at 45:55) under a pressure of between 10 psi and 20 psi. The fractions containing taxanes were collected and analyzed by thin layer chromatography (TLC) and subsequently combined according TLC results.
The fractions collected were then concentrated under vacuum, the resulting material was dissolved in methanol and kept at room temperature overnight. The crystal formed was filtered out and washed with methanol, then recrystallized from acetone. 13-Acetyl-9-dihydrobaccatin III was obtained as white crystal.
The mother liquor was concentrated to dryness and the residue was dissolved in acetone. The acetone solution was mixed with a polymeric resin (DowexTM resin, polystyrene-DVB). The mixture was evaporated under vacuum to remove acetone.
The resulting powder was subjected to low pressure chromatography. The industrial scale (150 mm x 1500 mm) chromatographic column was packed with DowexTM resin and eluted with acetone:water (45:55, vlv) at a flow rate 150 mI/mm under a operating pressure of 30 psi. Fractions of approximately 2L/each were collected and these were monitored by TLC and HPLC. The fractions which contained baccatin III and 10-deacetylbaccatin III were combined and evaporated under vacuum to remove substantially all of the organic solvent, then diluted with water and extracted with CH2CI2. The extract was then concentrated to dryness and the resulting residue was then dissolved in EtOAc and purified by normal phase silica gel column with hexane:EtOAc as the solvent system (start 5:5 end at 35:65). The baccatin III and 10-deacetylbaccatin- III was finally obtained as white powder with a purity of greater than 98%.
The fractions which contained paclitaxel and cephalomanine were combined and evaporated under vacuum to remove substantially all of the acetone, then partitioned between water and CH2CIZ. The organic layer was separated and evaporated to dryness under vacuum. The residue was dissolved in methanol. To the methanol solution approximately 30% (w/v) of water was added and the mixture was warmed to 60 C for five minutes. then kept in room temperature overnight. The crude crystalline solid from the methanol solution was filtered out and dried under vacuum between 70 C and 75 C. The solid was analyzed by HPLC. It consisted approximately 70% of paclitaxel and 25% of cephalomanine, and some other taxanes.
The crude paclitaxel can be processed according to one of three alternative procedures. In a first possibility, it was dissolved in acetone and purified by reverse phase column chromatography. The column was packed with polymeric resin (DiaionTM resin, HP2MG) and eluted with acetonitrile:water (45,55). Paclitaxel was obtained as white crystal with a purity of greater than 99%. Cephalomanine was obtained as a white powder in a purity of greater than 98%.
Alternatively, as a second processing approach, the purification of paclitaxel and cephalomanine was carried out through a chemical reaction process and then purified by bonded silica gel reverse phase column chromatography. The crude paclitaxel, cephalomanine mixture was dissolved in CHZCIZ or CHC13 (1:10, w/v), and reacted with 10 equivalent of bromine in a round bottom flask that placed in an ice bath (between 0 C and C) for approximately 40 minutes. The resulting mixture of paclitaxel and 2",3"-bromocephalomanine were readily separated by a reverse phase chromatographic column (C18 or phenyl), eluting solvent CH3CN:H20 (45:55). Paclitaxel was obtained as white crystal in a purity of greater than 99%. 2",3"-bromocephalomanine was obtained as a mixture of diastereomers, which were reacted with activated zinc in acetic acid at room temperature, and then purified by flash column chromatography to obtain pure cephalomanine having a purity of greater than 95%.
In a third alternative, the paclitaxel and bromocephalomanine were purified through normal phase silica gel column. The eluting solvent systems may comprise hexane:EtOAc (start 6:4 end at 4:6), or CHzCIz:MeZCO (start 8:2 end at 65:35) or CHCI2:EtOAc (start 75:25, end 6:4). From this method, paclitaxel was obtained as white crystal with a purity exceeding 99%, with cephalomanine present in an amount of less than 0.2%.
Having discussed the invention, more precise reference will now be made to the invention by way of the examples.
Approximately 200 kilograms of dried needles and twigs of Taxus canadensis were extracted with 1,000 liters of methanol at 60 C in an industrial multi-functional extractor for five hours and then filtered. The raw materials were extracted with 700 liters of methanol at a temperature of between 55 C and 60 C for another four hours and filtered.
The filtrate was combined and mixed with 10 kilograms of activated carbon (5% w/w) and kept at room temperature for one hour, then filtered to remove the activated carbon. The filtrate was then concentrated to approximately 100 liters under vacuum, then 300 liters of water:
dichloromethane (1:1) was added. The organic layer was collected and the aqueous solution was extracted two more times with 200 liters of dichloromethane. The dichloromethane solution was combined and evaporated under vacuum to become a slurry form, then diluted with 20 liters of acetone.
The acetone solution was coated on to 20 kilograms of Celite 545. The coated material was air dried and was then loaded on to the top of three low pressure industrial chromatographic columns (dimension: 150 x 15 cm). Each column was packed with kilograms of alumina oxide (AI203) absorbent. It will be appreciated that the exact dimension of the columns is not crucial as long as the columns are sufficiently large to hold the amount of A1203 required for the separation. Use of alumina oxide is effective to absorb flavonoids and lignans which are co-extracted from the source material. These are also difficult to remove and become a problem for the final purity of the product paclitaxel.
The columns were eluted with the solvent system hexane:acetone (start 100:0 end at 45:55) under a pressure between 10 and 15 psi with a flow rate at approximately 150 mI/min.
The fractions containing taxanes were collected and combined according to thin layer chromatography (TLC) results, and were then concentrated under vacuum to remove all solvents. The resulting material was dissolved in methanol and kept at room temperature overnight to yield needle-like crystals. The crystals were filtered and recrystallized from acetone to further yield white needle-like crystals identified as 13-acetyl-9dihydrobaccatin III, having a purity of greater than 96% yield (148 grams) (0.074% based on the raw material).
The mother liquid from the 13-acetyl-9dihydrobaccatin III crystallization was concentrated to dryness under vacuum. The residue was dissolved in three liters of acetone. The acetone solution was mixed with 1.5 kilograms of a polystyrene-divinylbenzene, copolymer resin. The mixture was evaporated to remove the solvent and the resulting powder was loaded on the top of a low pressure industrial chromatographic column packed with polystyrene-divinylbenzene copolymer resin, and eluted with 45%
acetone in water at a flow rate of 150 ml/min. under an operating pressure below than 30 psi. Fractions of 2 L/each were collected and these were monitored by TLC and HPLC.
The fractions which contained paclitaxel and cephalomanine were combined and evaporated under vacuum to remove most of the acetone, then diluted with deionized water and extracted three times with 2.5 liter of dichloromethane. The organic layer was concentrated to dryness under vacuum, the residue was dissolved in one liter of methanol.
To the methanol solution, approximately 30% (w/v) of water was added and the mixture was warmed to 60 C for a few minutes then kept at room temperature overnight.
The crude crystalline solid from the methanol solution was filtered out and dried in a vacuum oven at a temperature of between 70 C and 75 C. The solid consisted of approximately 70% paclitaxel and 25% cephalomanine in a yield of 31 grams.
The crude paclitaxel (30 g) was dissolved in 200 ml of acetonitrile and diluted with 250 ml of deionized water and pumped into the top of a low pressure chromatography column (size: 10 x 150 cm) and packed with a polymer resin (Diaion, macroporous polymethacrylate resin). After the sample was pumped, the column was eluted with a step gradient of 35, 40, 45 and 50% acetonitrile in water. The change of solvent was indicated by the results of the TLC and HPLC of the fractions.
Fractions of approximately 1 L/each were collected and monitored by TLC and HPLC
analysis. The flow rate was 75 mI/min. The column fractions which contained paclitaxel or cephalomanine were combined individually. The two combined solutions were allowed to stand at a temperature of approximately 5 C until crystallization of the individual compound was completed.
The crystals were filtered separately and both were recrystallized from 65 C
methanol in water.
Paclitaxel was obtained as white needle-like crystals with a purity of greater than 99% and a yield of 18.5 g (0.009%).
Cephalomanine was obtained as white needles with a purity of greater than 98%
and a yield of 6.5 g (0.003%).
The fractions contained baccatin III and 10-deacetylbaccatin III from the previous step were combined and evaporated under vacuum to remove substantially acetone, then partitioned between three liters of water and dichloromethane (1:1 v/v). The organic layer was concentrated to dryness and the residue was subjected for normal phase chromatography. The dimension of the column used was 4" x 4', packed with silica gel (200-300 mesh). The eluting solvent was a step gradient of hexane:ethyl acetate (start 50:50 end at 35:65). Fractions of approximately 1,000 ml/each were collected and each was monitored by TLC.
The fractions contained baccatin III or 10-deacetylbaccatin III were separately collected and combined according TLC results, then concentrated to dryness.
Fractions of approximately 1 L/each were collected and monitored by TLC and HPLC
analysis. The flow rate was 75 mI/min. The column fractions which contained paclitaxel or cephalomanine were combined individually. The two combined solutions were allowed to stand at a temperature of approximately 5 C until crystallization of the individual compound was completed.
The crystals were filtered separately and both were recrystallized from 65 C
methanol in water.
Paclitaxel was obtained as white needle-like crystals with a purity of greater than 99% and a yield of 18.5 g (0.009%).
Cephalomanine was obtained as white needles with a purity of greater than 98%
and a yield of 6.5 g (0.003%).
The fractions contained baccatin III and 10-deacetylbaccatin III from the previous step were combined and evaporated under vacuum to remove substantially acetone, then partitioned between three liters of water and dichloromethane (1:1 v/v). The organic layer was concentrated to dryness and the residue was subjected for normal phase chromatography. The dimension of the column used was 4" x 4', packed with silica gel (200-300 mesh). The eluting solvent was a step gradient of hexane:ethyl acetate (start 50:50 end at 35:65). Fractions of approximately 1,000 ml/each were collected and each was monitored by TLC.
The fractions contained baccatin III or 10-deacetylbaccatin III were separately collected and combined according TLC results, then concentrated to dryness.
The baccatin III part was dissolved in 200 ml of methanol and kept in a refrigerator overnight. The white crystals formed were filtered out and recrystallized from methanol to yield baccatin III as white crystals in a yield of 7.5 g (0.003%).
The crude 10-deacetylbaccatin III was dissolved in 150 ml acetone and then diluted with 150 ml of hexane. The mixture was kept at room temperature overnight. The white crystals formed were filtered and recrystallized from same solvent to yield 10-deacetylbaccatin III as white crystals. The yield was 15 g (0.007%).
Using similar apparatus and methodology as used in Example 1, crude paclitaxel was obtained. The crude paclitaxel was dissolved in 300 ml of dichloromethane which was added to a 1,000 ml three neck round bottom flask. The flask was replaced in an ice-bath and the solution stirred with a magnetic stirrer. When the temperature reached approximately 5 C, a solution of bromine (10 equivalents) in dichloromethane (1:1 v/v) was added slowly with stirring. The cephalomanine to bromine ratio was 1 to 10 moles.
The brominating was monitored by TLC analysis between five and 10 minutes. The reaction mixture was then diluted with 300 ml of dichloromethane and transferred to a separatory funnel after the reaction was completed (completion time required between 40 and 50 minutes). To the reaction mixture, 350 ml of 10% aqueous sodium thiosulfate (NazSz03) was added to absorb any excess bromine. The dichloromethane layer was separated and washed with water and brine, and then concentrated to dryness under vacuum. A light brown powder was obtained.
The crude material (10 g) from Example 2 was dissolved in 120 ml of acetonitrile which was diluted with 150 ml of deionized water. The solution was pumped into the top of a reverse phase chromatography column (5 x 100 cm) packed with C18 bonded silica gel.
The column was eluted with acetonitrile:water (45:55) under an operating pressure of between 30 and 40 psi. The flow rate was 30 mI/min. The fractions were collected (250 ml/each), monitored by TLC and combined.
The portion containing paclitaxel was refrigerated overnight; the crystals formed were filtered and recrystallized from 70% methanol. Paclitaxel was obtained as white needle-like crystals having a purity of greater than 99% in a yield of 6:1 g.
The fractions containing 2",3"-bromocephalomanine were combined, which partitioned between water and dichloromethane. The organic layer was collected and evaporated to dryness under vacuum. The residue was dissolved in 150 ml of methanol, which was diluted with 50 ml of water to obtain needle-like crystals. The off-white crystal was recrystallized from methanol:water to yield 2",3"-bromocephalomanine as white 10 crystals.
Two grams of 2",3"-bromocephalomanine were dissolved in 30 ml of AcOH and freshly activated zinc (2 g) was added. The mixture was stirred for three hours at room temperature and the reaction was monitored by TLC. After TLC analysis showed the reaction was completed, the mixture was partitioned between dichloromethane and 10%
NaHCO3 (300 ml, 2:1). The organic layer was washed with water and concentrated to dryness. The crude product was purified by flash chromatography to give cephalomanine as white powder. The crude product was purified by flash chromatography to yield cephalomanine as white powder.
The crude material (10 g) from Example 2 was dissolved in 120 ml of dichloromethane. The organic layer was concentrated to dryness and the residue was subjected for normal phase chromatography. The dimension of the column used was 4" x 4' packed with silica gel (between 200 and 300 mesh). The eluting solvent was a step gradient of dichloromethane:ethyl acetate (start 75:25 end at 6:4), for the separation of paclitaxel and 2",3"-bromocephalomanine the solvents system of hexane:ethyl acetate (start 6:4 end at 4:6) and dichloromethane:acetone (start 8:2 end at 65:35) also can be used.
Fractions of approximately 500 ml/each were collected, and each was monitored by TLC.
The fractions contained paclitaxel and 2",3"-bromocephalomanine were separately collected and combined according TLC results, then concentrated to dryness.
The crude 10-deacetylbaccatin III was dissolved in 150 ml acetone and then diluted with 150 ml of hexane. The mixture was kept at room temperature overnight. The white crystals formed were filtered and recrystallized from same solvent to yield 10-deacetylbaccatin III as white crystals. The yield was 15 g (0.007%).
Using similar apparatus and methodology as used in Example 1, crude paclitaxel was obtained. The crude paclitaxel was dissolved in 300 ml of dichloromethane which was added to a 1,000 ml three neck round bottom flask. The flask was replaced in an ice-bath and the solution stirred with a magnetic stirrer. When the temperature reached approximately 5 C, a solution of bromine (10 equivalents) in dichloromethane (1:1 v/v) was added slowly with stirring. The cephalomanine to bromine ratio was 1 to 10 moles.
The brominating was monitored by TLC analysis between five and 10 minutes. The reaction mixture was then diluted with 300 ml of dichloromethane and transferred to a separatory funnel after the reaction was completed (completion time required between 40 and 50 minutes). To the reaction mixture, 350 ml of 10% aqueous sodium thiosulfate (NazSz03) was added to absorb any excess bromine. The dichloromethane layer was separated and washed with water and brine, and then concentrated to dryness under vacuum. A light brown powder was obtained.
The crude material (10 g) from Example 2 was dissolved in 120 ml of acetonitrile which was diluted with 150 ml of deionized water. The solution was pumped into the top of a reverse phase chromatography column (5 x 100 cm) packed with C18 bonded silica gel.
The column was eluted with acetonitrile:water (45:55) under an operating pressure of between 30 and 40 psi. The flow rate was 30 mI/min. The fractions were collected (250 ml/each), monitored by TLC and combined.
The portion containing paclitaxel was refrigerated overnight; the crystals formed were filtered and recrystallized from 70% methanol. Paclitaxel was obtained as white needle-like crystals having a purity of greater than 99% in a yield of 6:1 g.
The fractions containing 2",3"-bromocephalomanine were combined, which partitioned between water and dichloromethane. The organic layer was collected and evaporated to dryness under vacuum. The residue was dissolved in 150 ml of methanol, which was diluted with 50 ml of water to obtain needle-like crystals. The off-white crystal was recrystallized from methanol:water to yield 2",3"-bromocephalomanine as white 10 crystals.
Two grams of 2",3"-bromocephalomanine were dissolved in 30 ml of AcOH and freshly activated zinc (2 g) was added. The mixture was stirred for three hours at room temperature and the reaction was monitored by TLC. After TLC analysis showed the reaction was completed, the mixture was partitioned between dichloromethane and 10%
NaHCO3 (300 ml, 2:1). The organic layer was washed with water and concentrated to dryness. The crude product was purified by flash chromatography to give cephalomanine as white powder. The crude product was purified by flash chromatography to yield cephalomanine as white powder.
The crude material (10 g) from Example 2 was dissolved in 120 ml of dichloromethane. The organic layer was concentrated to dryness and the residue was subjected for normal phase chromatography. The dimension of the column used was 4" x 4' packed with silica gel (between 200 and 300 mesh). The eluting solvent was a step gradient of dichloromethane:ethyl acetate (start 75:25 end at 6:4), for the separation of paclitaxel and 2",3"-bromocephalomanine the solvents system of hexane:ethyl acetate (start 6:4 end at 4:6) and dichloromethane:acetone (start 8:2 end at 65:35) also can be used.
Fractions of approximately 500 ml/each were collected, and each was monitored by TLC.
The fractions contained paclitaxel and 2",3"-bromocephalomanine were separately collected and combined according TLC results, then concentrated to dryness.
The paclitaxel part was dissolved in 100 ml of methanol and diluted with 35 ml of water, then kept refrigerated. The white crystals formed were filtered and recrystallized from methanol:water to yield paclitaxel (5.5 g) as white crystals).
The crude 2",3"-bromocephalomanine was dissolved in 50 ml acetone and then diluted with 50 ml of hexane. The mixture was kept at room temperature overnight. The white crystals formed were filtered and recrystallized from same solvent to yield 2",3"-bromocephalomanine as white crystals.
The following examples illustrate the compounds in structural form.
O
O OH
N)EI= I
_ \0.....,.,..
O OH O
HO O >H3 O
Paclitaxel 0 CH3 ~
O
OH
o,,,,,.....
O
O
Oo CH3 O
Cephalomanine RO O
OH
HO ,,.....
= O
H =
HO O
O
O
Baccatin III = R = CH3 10-deacetylbaccatin IV = R=H
The crude 2",3"-bromocephalomanine was dissolved in 50 ml acetone and then diluted with 50 ml of hexane. The mixture was kept at room temperature overnight. The white crystals formed were filtered and recrystallized from same solvent to yield 2",3"-bromocephalomanine as white crystals.
The following examples illustrate the compounds in structural form.
O
O OH
N)EI= I
_ \0.....,.,..
O OH O
HO O >H3 O
Paclitaxel 0 CH3 ~
O
OH
o,,,,,.....
O
O
Oo CH3 O
Cephalomanine RO O
OH
HO ,,.....
= O
H =
HO O
O
O
Baccatin III = R = CH3 10-deacetylbaccatin IV = R=H
O
OH
CH3 O õ.,.....
_ = = O
O
13-acetyl-9-dihydrobaccatin III
Although embodiments of the invention have been described above, it is not limited thereto and it will be apparent to those skilled in the art that numerous modifications form part of the present invention insofar as they do not depart from the spirit, nature and scope of the claimed and described invention.
OH
CH3 O õ.,.....
_ = = O
O
13-acetyl-9-dihydrobaccatin III
Although embodiments of the invention have been described above, it is not limited thereto and it will be apparent to those skilled in the art that numerous modifications form part of the present invention insofar as they do not depart from the spirit, nature and scope of the claimed and described invention.
Claims (20)
1. A method of isolating and purifying taxane analogues from a source containing taxanes, comprising:
extracting a source of taxanes in an organic extractant;
evaporating the organic extractant to obtain a slurry;
diluting the slurry with an organic solvent;
coating a weak absorbent medium with said diluted slurry containing the taxanes and loading said medium in a column, said column containing an absorbent agent;
eluting, in a first step, with an organic solvent mixture at a pressure of between 10 and 20 psi to generate fractions containing taxane compounds;
crystallizing said fractions to provide a solid taxane compound and a mother liquor;
concentrating said mother liquor; and eluting, in a second step, with a polar solvent mixture said mother liquor through a polymeric resin to provide at least a second taxane compound.
extracting a source of taxanes in an organic extractant;
evaporating the organic extractant to obtain a slurry;
diluting the slurry with an organic solvent;
coating a weak absorbent medium with said diluted slurry containing the taxanes and loading said medium in a column, said column containing an absorbent agent;
eluting, in a first step, with an organic solvent mixture at a pressure of between 10 and 20 psi to generate fractions containing taxane compounds;
crystallizing said fractions to provide a solid taxane compound and a mother liquor;
concentrating said mother liquor; and eluting, in a second step, with a polar solvent mixture said mother liquor through a polymeric resin to provide at least a second taxane compound.
2. The method as defined in claim 1, further including the step of removing lignan and flavonoid impurities in said first step.
3. The method as defined in claim 1, wherein said source of said taxanes comprises a plant source.
4. The method as defined in claim 3, wherein said plant source is selected from the group comprising Taxus brevifolia, Taxus baccata, Taxus walichiana, Taxus yunnanensis, and Taxus canadensis.
5. The method as defined in claim 3, wherein said taxanes include at least 13-acetyl-9-dihydrobaccatin III, 10-deacetylbaccatin III, baccatin III, cephalomanine or paclitaxel.
6. The method as defined in claim 1, wherein said organic extractant comprises dichloromethane.
7. The method as defined in claim 1, wherein said weak absorbent medium comprises Celite .TM.
545.
545.
8. The method as defined in claim 1, wherein said absorbent agent is aluminum oxide.
9. The method as defined in claim 1, wherein said organic solvent comprises hexane and acetone.
10. A method of isolating and purifying taxanes from a source containing taxanes, comprising:
providing a source of said taxanes;
extracting said taxanes from said source into an organic extraction medium to provide an organic layer containing taxane compounds;
evaporating the organic layer to obtain a slurry;
diluting the slurry with an organic solvent;
treating a support material with said diluted slurry;
providing a low pressure column containing an absorbent agent;
eluting, in a first step, an organic solvent through said column to elute purified taxane fractions;
crystallizing said taxane fractions to provide a first taxane analogue and a mother liquor;
eluting, in a second step, said mother liquor through a polymeric resin in a chromatographic column to purify and elute at least a second taxane analogue and a third taxane analogue; and collecting separated taxane analogues.
providing a source of said taxanes;
extracting said taxanes from said source into an organic extraction medium to provide an organic layer containing taxane compounds;
evaporating the organic layer to obtain a slurry;
diluting the slurry with an organic solvent;
treating a support material with said diluted slurry;
providing a low pressure column containing an absorbent agent;
eluting, in a first step, an organic solvent through said column to elute purified taxane fractions;
crystallizing said taxane fractions to provide a first taxane analogue and a mother liquor;
eluting, in a second step, said mother liquor through a polymeric resin in a chromatographic column to purify and elute at least a second taxane analogue and a third taxane analogue; and collecting separated taxane analogues.
11. The method as defined in claim 10, further including the step of removing lignan and flavonoid impurities in said first step.
12. The method as defined in claim 10, further including the step of grinding said source of taxanes after the step of providing a source of said taxanes and before the step of extracting said taxanes from said source into an organic extraction medium and wherein the extraction medium is methanol.
13. The method as defined in claim 12, wherein the extraction medium is mixed with charcoal, filtered and evaporated to form a concentrate.
14. The method as defined in claim 13, wherein said support material comprises Celite .TM. 545.
15. The method as defined in claim 10, wherein said organic solvent comprises a mixture of acetone and hexane.
16. The method as set defined claim 15, wherein said organic solvent is passed through said column at a pressure of between 10 and 20 psi.
17. The method as defined in claim 1, further including the step of collecting and analyzing said taxane fractions by thin layer chromatography.
18. A method of isolating and purifying taxanes from a source containing taxanes, comprising:
providing a source of said taxanes;
extracting said taxanes from said source into an organic extraction medium to provide an organic layer containing taxane compounds;
evaporating the organic layer to obtain a slurry;
diluting the slurry with an organic solvent;
treating a support material with said diluted slurry;
providing a low pressure column containing an absorbent agent;
eluting, in a first step, at a pressure of between 10 and 20 psi, an organic solvent through said column to elute purified taxane fractions and remove flavonoid and lignan impurities;
crystallizing said taxane fractions to provide a first taxane analogue and a mother liquor;
eluting, in a second step, at a pressure of 30 psi, said mother liquor through a polystyrene DVB resin in a chromatographic column to purify and elute at least a second taxane analogue and a third taxane analogue;
eluting, in a third step, said second taxane analogue and said third taxane analogue through a normal phase silica gel column to purify said second taxane analogue and said third taxane analogue; and collecting separated taxane analogues.
providing a source of said taxanes;
extracting said taxanes from said source into an organic extraction medium to provide an organic layer containing taxane compounds;
evaporating the organic layer to obtain a slurry;
diluting the slurry with an organic solvent;
treating a support material with said diluted slurry;
providing a low pressure column containing an absorbent agent;
eluting, in a first step, at a pressure of between 10 and 20 psi, an organic solvent through said column to elute purified taxane fractions and remove flavonoid and lignan impurities;
crystallizing said taxane fractions to provide a first taxane analogue and a mother liquor;
eluting, in a second step, at a pressure of 30 psi, said mother liquor through a polystyrene DVB resin in a chromatographic column to purify and elute at least a second taxane analogue and a third taxane analogue;
eluting, in a third step, said second taxane analogue and said third taxane analogue through a normal phase silica gel column to purify said second taxane analogue and said third taxane analogue; and collecting separated taxane analogues.
19. The method as defined in claim 18, wherein said second taxane analogue comprises baccatin III and said third taxane analogue comprises 10-deacetylbaccatin III.
20. The method as defined in claim 18, wherein said analogues have a purity of at least 98%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2258066 CA2258066C (en) | 1999-01-07 | 1999-01-07 | Isolation and purification of paclitaxel, and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2258066 CA2258066C (en) | 1999-01-07 | 1999-01-07 | Isolation and purification of paclitaxel, and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2258066A1 CA2258066A1 (en) | 2000-07-07 |
CA2258066C true CA2258066C (en) | 2009-06-16 |
Family
ID=29554916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2258066 Expired - Fee Related CA2258066C (en) | 1999-01-07 | 1999-01-07 | Isolation and purification of paclitaxel, and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2258066C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002214883A1 (en) | 2000-11-13 | 2002-05-21 | Lahu Saiji | Isolation of taxanes |
-
1999
- 1999-01-07 CA CA 2258066 patent/CA2258066C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2258066A1 (en) | 2000-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5969165A (en) | Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column | |
US5393896A (en) | Process for obtaining 10-deacetylbaccatin III | |
EP0774010B1 (en) | A method for mass production of taxol from taxus genus plant | |
US7880022B2 (en) | Method for separation and purification of 13-dehydroxybaccatin III and 10-deacetylpaclitaxel from taxans-containing materials | |
WO2002038556A2 (en) | Process for mass production of gmp paclitaxel and related taxanes | |
US7169307B2 (en) | Process for the extraction of paclitaxel and 9-dihydro-13-acetylbaccatin III from Taxus | |
EP1818328A1 (en) | Chromatographic method for the isolation and purification of taxane derivatives | |
US6229027B1 (en) | Process for manufacturing paclitaxel and 13-acetyl-9-dihydrobaccatin IV | |
EP1010697B1 (en) | Process for isolation of 14-b hydroxy-10-deacetyl baccatin-III | |
US6878832B2 (en) | Isolation of taxanes | |
CA2258066C (en) | Isolation and purification of paclitaxel, and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column | |
US20070190623A1 (en) | Process for purification and recovery of paclitaxel compounds | |
CA2203844C (en) | Process for the isolation of paclitaxel and 9-dihydro-13-acetylbaccatin iii | |
MXPA00000318A (en) | Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column | |
KR100259396B1 (en) | Method for mass production of high purity taxol from taxus genus plant | |
RU2373198C2 (en) | METHOD OF PRODUCING PACLITAXEL FROM Taxus GENUS PLANTS | |
KR100259395B1 (en) | Method for mass production of high purity taxol form taxus genus plant | |
CZ200070A3 (en) | Isolation and purification of paclitaxel and other related taxanes by industrial low-pressure polymeric column chromatography | |
AU2006201733B2 (en) | Process for manufacturing paclitaxel and 13-acetyl-9-dihydrobaccatin III | |
UA68355C2 (en) | Method for isolating and purifying taxan analogues, in particular paclitaxel (variants) | |
KR0150347B1 (en) | A method for isolating taxol from taxus genus plant by crystallization | |
CA2536000C (en) | Process for the extraction of paclitaxel and 9-dihydro-13-acetylbaccatin iii from taxus | |
KR0150339B1 (en) | A method for isolating taxol from taxus genus plant by fractional precipitation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |